The economy and business portal Turkishtime published its ninth annual R&D 250 research. Based on 2021 data, Ali Raif became one of the “Highest R&D Spenders in Turkey” and placed fifth in all industries and fourth in the pharmaceutical industry in terms of the number of trademarks obtained in the R&D center.
Ali Raif draws on its 59 years of industry experience and all-national capital to add value to life and provide quality services and products to protect and improve people’s health. Ali Raif’s long R&D experience enables us to continuously invest in innovation and introduce new products to the industry at our R&D center registered in 2017.
With 54 projects and 21 trademarks, in 2020, Ali Raif’s R&D activities focused on innovative and high-value projects on pharmaceutical equivalents. In 2021, we significantly increased our R&D expenditures by launching 45 projects and obtaining 45 trademarks while registering one national and one international patent.
Consequently, Ali Raif ranked among the “top 250 companies with the highest R&D expenditures in Turkey” and placed fifth in all industries and fourth in the pharmaceutical industry in terms of the number of trademarks obtained in the R&D center according to the R&D 250 research by Turkishtime.
Ali Raif produces effective, differentiated pharmaceutical forms for patients and doctors in the current and target treatment areas. Our easy-to-use innovative products help improve patient compliance. Ali Raif prioritizes the employment of women, as women hold 75 percent of jobs and 70 percent of executive positions at our R&D Center. Additionally, the company offers postgraduate education support to its researchers to upgrade their personal skills and improve team efficiency. In addition to developing new products, Ali Raif R&D center cherishes cooperation between the pharmaceutical industry and universities. By supporting trainings, symposiums, and conferences in this area, the R&D team aims to help students learn more about the business and encourage them to join the pharmaceutical industry and be a stakeholder.
Ali Raif ranks in the top 20 companies in the Turkish pharmaceutical industry with over 200 products and new brands on the market. Consistently investing in the future, the company launched the construction of its second production plant in 2021. The aim is to quadruplicate the current production capacity, create new jobs, open new production lines to produce different forms, expand the R&D center, and diversify new product research. Ali Raif ultimately intends to improve export sales.
